Skip to content
GLOBALANCE INTELLIGENCEThe economy ahead.
This Week Index 28/100 Sign in
Money & Investments › GI 100 Index
The Great Value ShiftInvestment ThemesGI 100 IndexGI PortfolioStart Future Check
AI FOOTPRINTlimitedASSESSMENT 2026GLOBALANCEINTELLIGENCE
Globalance AI Footprint

Assessment as of November 2026 · next assessment 2027.

Result of the assessment by the Globalance research team under the published methodology. Not a certification or quality label.

How we assess ›

How this rating is builtVideo · 0:52
GI 100 Index · Profile

AstraZeneca PLC

United KingdomAdoptersAssignment FullData quality Medium

Key messagelimited AI Footprint

AstraZeneca has published principles for the ethical use of data and AI and trains tens of thousands of employees in working with AI, but provides little evidence of how the rules are checked and monitored in day-to-day practice. On the protection of data and systems, the company reports no material security incidents for 2024 and 2025, while in China criminal proceedings are under way against a subsidiary over the unlawful collection of patient data.

Opportunities

  • Safetysolid

    For technical data and system protection there is grade B evidence: zero material cyber incidents and zero material breaches of personal data in 2024 and 2025, according to the company part of the Sustainability Statement reviewed by KPMG with limited assurance (S18), as well as the ISO/IEC …

    For technical data and system protection there is grade B evidence: zero material cyber incidents and zero material breaches of personal data in 2024 and 2025, according to the company part of the Sustainability Statement reviewed by KPMG with limited assurance (S18), as well as the ISO/IEC 27001:2022 certification of Evinova by BSI (S22). There is no evidence of testing, validation, red-teaming and monitoring of its own AI systems; the TROP2 companion diagnostic using the AstraZeneca QCS platform has only a Breakthrough Designation (S35). The pillar contains a medium controversy without an AI link (indictment in China over the unlawful collection of personal data, S31, S32) and an unconfirmed hacking attack (S29, S30); the rating “solid” rests essentially on one sub-criterion.

Risks

  • Responsibilitylimited

    AstraZeneca publishes principles on data and AI ethics and states that it has introduced an AI governance framework, a risk framework and a playbook (S09); the Chief Data Officer describes an AI risk process in the Enterprise Data Office and a combined review of data protection, security and AI (S24, S25).

    AstraZeneca publishes principles on data and AI ethics and states that it has introduced an AI governance framework, a risk framework and a playbook (S09); the Chief Data Officer describes an AI risk process in the Enterprise Data Office and a combined review of data protection, security and AI (S24, S25). These statements are self-descriptions without verifiable procedural documentation; the terms of reference of the Science and Sustainability Committees contain no responsibility for AI (S12, S40), and the governance chapter of the 2025 annual report was not readable (S03). The external ethics audit of 2021 and the description of the AI Resolution Board and risk classes lie outside the research period (S10, S11).

  • Transparencylimited

    In its principles, AstraZeneca commits to being open about the benefits, strengths and limitations of AI and to telling people when they are interacting with an AI system (S09), and in the Form 20-F it openly names risks such as bias and malfunction (S01).

    In its principles, AstraZeneca commits to being open about the benefits, strengths and limitations of AI and to telling people when they are interacting with an AI system (S09), and in the Form 20-F it openly names risks such as bias and malfunction (S01). The company describes in reports where AI is used (S02, S20), without documenting model or system information, labelling practice or transparency reports. There is therefore only grade C evidence.

  • Risk area

    AI in diagnostics and patient contact, such as X-ray screening and follow-up care

  • Risk area

    Evinova AI platform for clinical trials, also used by third parties

  • No serious controversy recorded.

What lies behind the assessment

Research of 3 November 2026
40searches
40pages and documents read
8primary documents
2controversies checked
5open points, named openly
The full research: pillars, evidence, controversies and open points
AI Footprint · Adopter · As of 3 November 2026
AstraZeneca PLCOverall rating: limited

AstraZeneca has published principles on data and AI ethics and reports no material cyber incidents for 2024 and 2025. How its own AI systems are tested and who oversees AI at board level is not documented.

Responsibility

40 %
limitedsolidstrong

Principles and responsible managers are named, but board-level oversight of AI is not.

  • +Published principles on data and AI ethics Source ↗
  • +AI training with more than 50,000 participants in 2025 Source ↗
  • –Committee terms of reference assign no responsibility for AI Source ↗
  • –Framework, risk process and playbook only as self-description Source ↗
  • –No current external audit of AI governance
All sources for this pillar (18)

Safety

40 %
limitedsolidstrong

No material cyber incidents in 2024 and 2025, but testing of its own AI systems is not documented.

  • +Zero material cyber incidents and data breaches in 2024 and 2025 Source ↗
  • +ISO/IEC 27001:2022 for Evinova, certified by BSI Source ↗
  • –No evidence of testing and monitoring of its own AI systems
  • –Indictment in China over the unlawful collection of patient data Source ↗
  • –Unconfirmed claim of data theft by Lapsus$ Source ↗
All sources for this pillar (11)

Transparency

20 %
limitedsolidstrong

The principles promise openness about AI, but labelling and model information are not documented.

  • +Principle of informing people about interactions with AI Source ↗
  • +Form 20-F names bias and malfunction as AI risks Source ↗
  • –No documented labelling for the AZerca follow-up system
  • –No model or system cards for QCS, Evinova and Modella
All sources for this pillar (8)
What is missing for “strong”

These steps are in the company’s own hands.

1Responsibility
Disclose board-level oversight of AI

Assign responsibility for AI to a board committee and publish the framework, risk process and playbook and have them externally audited.

2Safety
Document testing of its own AI systems

Disclose validation, red-teaming and monitoring of QCS, Evinova, the Modella models and AZerca.

3Transparency
Label AI in patient contact

Document labelling in patient contact and publish system cards with limitations and error rates.

Context: 101 companies assessed

Distribution of overall ratings, no ranking
strong
none yet
solid
limited
← AstraZeneca PLC is one of 66

No company reaches “strong” today. Disclosure on how companies handle AI is still young across the market.

Controversies
2 1 medium, 1 minor

No deduction for controversies.

Largest risk area
AI errors in patient contact

No validation or monitoring procedures are documented for X-ray screening, echocardiography, the AZerca follow-up system or the QCS pathology platform.

How thoroughly assessed
37 Evidence

8 primary documents read, 40 searches.

Read the full reasoning and all sources
AstraZeneca PLC · Full reasoning

Principles on data and AI ethics, but little evidence of oversight and testing

Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.

1 · Responsibility

limitedWeight 40%

AstraZeneca describes an AI governance framework and an AI risk process, but both are documented only as self-description without verifiable procedural documentation.

What is documented
  • The principles provide for governance proportional to impact and risk and for a review of the data protection standards of third-party AI providers8
  • The Chief Data Officer describes an AI risk process in the Enterprise Data Office and a combined review of data protection, security and AI5 9
  • At management level, the Chief Digital Officer, the Chief Data Officer and the role of Director of Data and AI Policy are named4 5 6
  • More than 50,000 employees took part in the “Thriving in the Age of AI” programme in 2025; more than 17,000 are AI-certified7 14
  • The AZethics reporting channels are operated by an independent third party15 13
The case against
Board-level oversight not documented
  • The terms of reference of the Science Committee (June 2025) and the Sustainability Committee (January 2026) contain no responsibility for AI2 3
  • The governance chapter of the 2025 annual report was technically unreadable, and the Audit Committee's terms of reference could not be retrieved18
Self-description without audit
  • The framework, risk framework and playbook are not public; the statements about them are self-descriptions8 5
  • The external ethics audit of 2021 and the AI Resolution Board of that time lie outside the research period16 11
  • The sustainability data annex contains no AI figures17
Sources for Responsibility (18)
  1. AstraZeneca PLC: Corporate governance (web page) · 3 November 2026 · secondary source
  2. AstraZeneca PLC: Science Committee – Terms of Reference · 1 June 2025 · secondary source
  3. AstraZeneca PLC: Sustainability Committee – Terms of Reference · 1 January 2026 · secondary source
  4. AstraZeneca: How we're upskilling and preparing our workforce for the age of AI · 11 April 2025 · secondary source
  5. CDO Magazine: Should AI Governance Stand on Its Own? AstraZeneca CDO Weighs In · 13 November 2025 · secondary source
  6. Pink Sheet (Citeline): AstraZeneca: AI Regulations 'Tricky' To Interpret & Navigate · 15 November 2024 · secondary source
  7. AstraZeneca PLC / U.S. SEC (EDGAR): Annual Report and Form 20-F Information 2025 (Exhibit 15.1) · 24 February 2026 · secondary source
  8. AstraZeneca: Data and AI ethics (web page) · 1 January 2026 · secondary source
  9. CDO Magazine: Inside AstraZeneca's AI Strategy: CDO Brian Dummann on Innovation, Governance, and Speed · 29 October 2025 · secondary source
  10. AstraZeneca PLC / U.S. SEC (EDGAR): Form 20-F for the fiscal year ended December 31, 2025 (main document) · 24 February 2026 · secondary source
  11. Mökander, Sheth, Gersbro-Sundler, Blomgren (AstraZeneca), Floridi, arXiv / Frontiers in Computer Science: Challenges and Best Practices in Corporate AI Governance: Lessons from the Biopharmaceutical Industry Wolfstre
  12. AstraZeneca: AstraZeneca Standard – Data Privacy (STND-0002094, Version 6.0) · 1 January 2023 · secondary source
  13. AstraZeneca: Sustainability Impact Publication 2026 · 1 April 2026 · secondary source
  14. Fortune (Sheryl Estrada): How AstraZeneca's 17,000 AI-certified employees are helping it reach a 'stretch goal' of $80 billion in revenue · 30 April 2026 · secondary source
  15. AstraZeneca: Code of Ethics (English) · 3 November 2026 · secondary source
  16. Jakob Mökander, Luciano Floridi (Oxford Internet Institute), arXiv / AI and Ethics: Operationalising AI governance through ethics-based auditing: An industry case study · 31 December 2021 · secondary source
  17. AstraZeneca: Sustainability Data Annex 2025 · 3 November 2026 · primary source
  18. AstraZeneca PLC: Annual Report and Form 20-F Information 2025 (PDF) · 24 February 2026 · secondary source

2 · Safety

solidWeight 40%

Data and system protection is documented with figures and a certificate for Evinova, whereas validation and monitoring of its own AI systems are not.

What is documented
  • The 2025 data annex reports zero material cyber incidents and zero material breaches of personal data for 2024 and 20254
  • Evinova's information security management system is certified to ISO/IEC 27001:2022 by BSI6
  • The data privacy standard governs risk assessment, third-party due diligence and incident reporting7
  • The Form 20-F names unreliability and malfunction as risks of AI3
The case against
Missing evidence of AI testing
  • There is no information on validation, testing, red-teaming and monitoring of QCS, the Evinova agents, the Modella models and AZerca
  • The TROP2 companion diagnostic using the QCS platform has an FDA Breakthrough Designation, but no documented approval1
  • According to the company, the figures were reviewed by KPMG; the separate KPMG report on the data annex does not cover them4 5
Incidents and proceedings
  • According to the indictment by the Shenzhen prosecutor, the Chinese subsidiary allegedly collected patient data unlawfully; no AI link is documented8 9
  • Lapsus$ claims to have stolen around 3 GB of internal data; AstraZeneca has neither confirmed nor commented on this10 11
  • No public channel for reporting vulnerabilities was found
Sources for Safety (11)
  1. Roche (via BioSpace): Roche granted FDA Breakthrough Device Designation for first AI-driven companion diagnostic for non-small cell lung cancer · 29 April 2025 · secondary source
  2. Evinova / Business Wire: Evinova: strategic collaboration with Astellas, AstraZeneca and Bristol Myers Squibb for the AI-native platform · 18 February 2026 · secondary source
  3. AstraZeneca PLC / U.S. SEC (EDGAR): Form 20-F for the fiscal year ended December 31, 2025 (main document) · 24 February 2026 · secondary source
  4. AstraZeneca: Sustainability Data Annex 2025 · 3 November 2026 · primary source
  5. KPMG LLP: Independent limited assurance report – Sustainability Data Annex 2025 · 8 April 2026 · primary source
  6. Evinova (AstraZeneca Group): Evinova Secures ISO 27001 Certification, Elevating Data Security Standards · 18 March 2026 · primary source
  7. AstraZeneca: AstraZeneca Standard – Data Privacy (STND-0002094, Version 6.0) · 1 January 2023 · secondary source
  8. Fierce Pharma: China indicts AstraZeneca and former exec Leon Wang over data, trade charges · 1 November 2025 · secondary source
  9. Pharmaceutical Executive: Former AstraZeneca executive charged with several offenses in China · 12 February 2026 · secondary source
  10. SecurityWeek: Extortion Group Claims It Hacked AstraZeneca · 26 March 2026 · secondary source
  11. Bitdefender (Hot for Security): Lapsus$ claims AstraZeneca breach exposes code and credentials · 26 March 2026 · secondary source

3 · Transparency

limitedWeight 20%

AstraZeneca promises to inform people when they interact with AI, but documents neither labelling nor model or system information on its own tools.

What is documented
  • The principles commit to being open about the benefits, strengths and limitations of AI and to disclosing interactions with AI1
  • The Form 20-F names bias, unreliability and malfunction as risks of AI4
  • Annual and sustainability reports describe uses of AI in research, screening and follow-up care2 3
  • According to the company, more than 40 per cent of its genomic data comes from under-represented population groups5
The case against
Missing disclosure
  • No model or system cards were found for QCS, the Evinova agents and the Modella models
  • Labelling towards patients for AZerca and screening applications is not documented
  • There is no stand-alone responsible AI or transparency report8
  • Information on the limitations and error rates of individual products is missing
Sources for Transparency (8)
  1. AstraZeneca: Data and AI ethics (web page) · 1 January 2026 · secondary source
  2. AstraZeneca PLC / U.S. SEC (EDGAR): Annual Report and Form 20-F Information 2025 (Exhibit 15.1) · 24 February 2026 · secondary source
  3. AstraZeneca: Sustainability Impact Publication 2026 · 1 April 2026 · secondary source
  4. AstraZeneca PLC / U.S. SEC (EDGAR): Form 20-F for the fiscal year ended December 31, 2025 (main document) · 24 February 2026 · secondary source
  5. AstraZeneca PLC: Sustainability Investor Call July 2026 (presentation) · 6 July 2026 · secondary source
  6. Tissue Pathology (reproducing the Modella AI announcement): Modella AI Announces Acquisition by AstraZeneca to Advance AI-Driven Oncology R&D at Global Scale · 14 January 2026 · secondary source
  7. Evinova / Business Wire: Evinova: strategic collaboration with Astellas, AstraZeneca and Bristol Myers Squibb for the AI-native platform · 18 February 2026 · secondary source
  8. AstraZeneca: Sustainability resources (web page) · 3 November 2026 · secondary source

4 · Why the harm rule does not apply

The harm rule does not apply: in the research period there is no judgment, no authority decision and no fine concerning AI systems, and the ongoing indictment in China concerns data protection without an AI link.

5 · Controversies (2)

6 · What remains open

  • Board or committee oversight of AI and cybersecurity; the governance chapter of the 2025 annual report was not readable
  • Current status and auditing of AI governance since 2022, such as inventory, approvals and audits
  • Validation and monitoring of its own AI systems such as QCS, the Evinova agents and the Modella models
  • Labelling of AI towards patients
  • Primary documents and outcome of the criminal proceedings against the Chinese subsidiary

7 · How it was assessed

Cut-off date: 3 November 2026 · 40 searches, 40 fetches.

Primary documents read (8)
  • Form 20-F 2025 (main document, Item 3.D) and Exhibit 15.1 (pp. 1–17)
  • Annual Report 2025 PDF and accessible version (pp. 1–24)
  • Form 20-F 2024 (Item 3.D) and Annual Report 2024 (pp. 1–24)
  • Data and AI ethics (webpage, January 2026)
  • Terms of Reference Science Committee (June 2025) and Sustainability Committee (January 2026)
  • Code of Ethics; Data Privacy Standard v6.0
  • Sustainability Data Annex 2025; KPMG assurance report on the Data Annex 2025; Sustainability Impact Publication 2026; Sustainability Investor Call July 2026
  • Evinova announcements on ISO 27001 certification and the AI platform

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0

We assess documented practice in dealing with AI; this is not an investment recommendation. Three pillars, weights 40/40/20, harm rule.

Research of 3 November 2026 under Globalance AI Footprint rulebook version 0. Documented observations from public sources, no investment recommendation.

Important Notice. This material is provided for information purposes only and does not constitute an offer or solicitation to buy or sell any financial instrument, nor does it constitute investment advice or a recommendation. The GI 100 Index is a rules-based strategy index of Globalance Bank. Investments involve risk, including the loss of capital invested. The final product documents (including FinSA) shall prevail in all cases.

Your company? Information on inclusion in the GI 100 Index →

What comes next